These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 23288215)

  • 1. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
    Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
    Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
    J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human complement factor H related protein test for monitoring bladder cancer.
    Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
    J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
    Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
    Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP;
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.
    Shariat SF; Casella R; Khoddami SM; Hernandez G; Sulser T; Gasser TC; Lerner SP
    J Urol; 2004 Feb; 171(2 Pt 1):626-30. PubMed ID: 14713774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
    Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
    J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
    Bhuiyan J; Akhter J; O'Kane DJ
    Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
    Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
    Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic role of survivin in urinary bladder cancer.
    Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
    Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of urinary survivin as a diagnostic marker in bladder cancer.
    Abd El-Hakim TF; El-Shafie MK; Abdou AG; Azmy RM; El-Naidany SS; Badr El-Din MO
    Anal Quant Cytopathol Histpathol; 2014 Jun; 36(3):121-7. PubMed ID: 25141488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
    Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
    Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
    Gibanel R; Ribal MJ; Filella X; Ballesta AM; Molina R; Alcaraz A; Alcover JB
    Anticancer Res; 2002; 22(2B):1157-60. PubMed ID: 12168917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.